Expert group to review evidence for use of medical cannabis for employer plans

World News: . []

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Today, Reformulary Group, Canada’s leading, independent drug plan management company, announced its Cannabis Formulary Committee, which will review the best available evidence for medical cannabis and provide expert opinions and criteria for its use in specific indications. 

The Cannabis Formulary Committee will recommend specific medical uses and develop criteria for appropriate use, lines of therapy, specific strains, form, grams per indication, mode of consumption and quantity limits. The Committee will advise on the creation of a registry to capture real-world patient-reported data. Data will be used to adapt the formulary where necessary and help patients and doctors make evidence-based decisions.   

“For Canadian employers that choose to cover medical cannabis, our cannabis formulary – called Cannabis Standard – will be an essential product to access the best available evidence and expert advice,” said Helen Stevenson, Reformulary Group founder and CEO. “By subscribing, an employer can be confident that their employees are following expert criteria on how and what to consume when it comes to medical cannabis and specific indications.”

The Cannabis Standard formulary will be available to employers on a subscription basis. Reformulary Group has established and will continue to develop partnerships with several Licensed Producers to ensure employers and individuals using the formulary receive preferred prices and access to customer care programs. These partnerships will also support the development of the registry.

Reformulary’s Cannabis Formulary Committee is comprised of experts who specialize in medical cannabis and/or evidence-based reviews, including:

More news and information about Reformulary Group

Published By:

Globe Newswire: 17:53 GMT Wednesday 16th May 2018

Published: .

Search for other references to "expert" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers